{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04761198",
      "orgStudyIdInfo": {
        "id": "MPH313-1-02"
      },
      "secondaryIdInfos": [
        {
          "id": "2020-004222-37",
          "type": "EUDRACT_NUMBER"
        }
      ],
      "organization": {
        "fullName": "Mereo BioPharma",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors",
      "officialTitle": "A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-03",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-03-23",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-10-30",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-10-30",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-02-12",
      "studyFirstSubmitQcDate": "2021-02-17",
      "studyFirstPostDateStruct": {
        "date": "2021-02-18",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2025-01-31",
      "resultsFirstSubmitQcDate": "2025-03-07",
      "resultsFirstPostDateStruct": {
        "date": "2025-03-17",
        "type": "ACTUAL"
      },
      "dispFirstSubmitDate": "2024-10-28",
      "dispFirstPostDateStruct": {
        "date": "2025-03-17",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-03-07",
      "lastUpdatePostDateStruct": {
        "date": "2025-03-17",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Mereo BioPharma",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "ICON Clinical Research",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \\[mg\\] every 2 weeks).",
      "detailedDescription": "This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 mg every 2 weeks) and will continue until either unacceptable toxicity or disease progression. Participants may continue to receive treatment beyond documented Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) or disease progression. Participants who are both checkpoint inhibitor (CPI) naive as well as participants who have received or progressed following a CPI will be eligible and include the following tumor types: head and neck squamous cell carcinoma (HNSCC), cervical carcinoma, gastric or gastroesophageal carcinoma, endometrial carcinoma, tumor mutation burden high (TMB-H), select rare tumors and ovarian carcinoma."
    },
    "conditionsModule": {
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "keywords": [
        "etigilimab",
        "nivolumab",
        "anti-TIGIT antibody",
        "MPH313",
        "Opdivo",
        "ACTIVATE"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Basket study",
        "primaryPurpose": "BASIC_SCIENCE",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 76,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
          "type": "EXPERIMENTAL",
          "description": "Participants with endometrial cancer CPI (programmed death-1 \\[PD-1\\]/ programmed death ligand-1 \\[PD-L1\\]) naive will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort B: Head and Neck Squamous Cell Carcinoma",
          "type": "EXPERIMENTAL",
          "description": "Participants with head and neck cell carcinoma will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort C: Cervical Carcinoma",
          "type": "EXPERIMENTAL",
          "description": "Participants with cervical carcinoma will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort D (Recurrent Advanced and/or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma)",
          "type": "EXPERIMENTAL",
          "description": "Participants with recurrent advanced and/or metastatic gastric or gastroesophageal junction adenocarcinoma will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort E: TMB-H + MSS Solid Tumors",
          "type": "EXPERIMENTAL",
          "description": "Participants with tumour mutational burden-high (TMB-H) and microsatellite stable (MSS) solid tumors will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
          "type": "EXPERIMENTAL",
          "description": "Participants with rare tumors (sarcoma, uveal melanoma, and germ cell) will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
          "type": "EXPERIMENTAL",
          "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Cohort H: Ovarian Cancer",
          "type": "EXPERIMENTAL",
          "description": "Participants with ovarian cancer will receive etigilimab in combination with nivolumab every 2 weeks and will continue treatment until protocol-defined discontinuation criteria are met.",
          "interventionNames": [
            "Drug: Etigilimab",
            "Drug: Nivolumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Etigilimab",
          "description": "IV infusion of IV etigilimab every 2 weeks",
          "armGroupLabels": [
            "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
            "Cohort B: Head and Neck Squamous Cell Carcinoma",
            "Cohort C: Cervical Carcinoma",
            "Cohort D (Recurrent Advanced and/or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma)",
            "Cohort E: TMB-H + MSS Solid Tumors",
            "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
            "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
            "Cohort H: Ovarian Cancer"
          ],
          "otherNames": [
            "MPH313"
          ]
        },
        {
          "type": "DRUG",
          "name": "Nivolumab",
          "description": "IV infusion of nivolumab every 2 weeks",
          "armGroupLabels": [
            "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
            "Cohort B: Head and Neck Squamous Cell Carcinoma",
            "Cohort C: Cervical Carcinoma",
            "Cohort D (Recurrent Advanced and/or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma)",
            "Cohort E: TMB-H + MSS Solid Tumors",
            "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
            "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
            "Cohort H: Ovarian Cancer"
          ],
          "otherNames": [
            "Opdivo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Objective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)",
          "description": "The ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1. CR: Disappearance of all target or non-target lesions and normalization of tumor marker level. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \\<10 millimeters (mm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.",
          "timeFrame": "From first dose of study drug until the date of first objective response (CR or PR) (maximum exposure: 638 days)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Number of Participants WithTreatment-emergent Adverse Events (TEAEs), Any Adverse Events of Special Interests (AESIs), AESI Immune Related AEs, and AESI Infusion Reactions",
          "description": "TEAEs were defined as adverse events (AEs) with an onset date on or after the date of first administration of study drug up to 100 days after the last dose of study drug and before starting any subsequent cancer treatment. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AESIs were defined as events (serious or non-serious) which were of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor might be appropriate. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.",
          "timeFrame": "From first dose of study drug until 100 days after the last dose of study drug or the initiation of any subsequent cancer treatment, whichever occurs first (maximum exposure: 638 days)"
        },
        {
          "measure": "Disease Control Rate (DCR) as Assessed Based on RECIST v1.1",
          "description": "The DCR was defined as the percentage of participants who achieved CR, PR, and stable disease (SD). CR: Disappearance of all target or non-target lesions and normalization of tumor marker level. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits; and no new lesions.",
          "timeFrame": "From first dose of study drug until the date of first BOR (CR, PR, or SD) (maximum exposure: 638 days)"
        },
        {
          "measure": "Duration of Response (DoR) as Assessed Based on RECIST v1.1",
          "description": "The DoR was defined as the time, in days, from the first of the 2 assessments required for confirmed PR or CR to the time of the progressive disease (PD) or death due to underlying cancer. CR: Disappearance of all target or non-target lesions and normalization of tumor marker level. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of the existing non-target lesions. The appearance of one or more new lesions was also considered progression.",
          "timeFrame": "From first dose of study drug until the date of first overall response of PD or date of death due to underlying cancer (maximum exposure: 638 days)"
        },
        {
          "measure": "Duration of Stable Disease (DoSD) as Assessed Based on RECIST v1.1",
          "description": "The DoSD was defined as the time, in days, from the first date of treatment until the first date at which PD was experienced or the participant died due to underlying cancer. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of the existing non-target lesions. The appearance of one or more new lesions was also considered progression.",
          "timeFrame": "From first dose of study drug until the date of first overall response of PD or date of death due to underlying cancer (up to a maximum of 680 days)"
        },
        {
          "measure": "Serum Concentrations of Etigilimab",
          "timeFrame": "Pre-infusion and 15 minutes post-infusion on Cycle 1 Day 1 and Cycle 4 Day 43"
        },
        {
          "measure": "Number of Participants With Anti-drug Antibodies (ADA) to Etigilimab",
          "timeFrame": "From first dose of study drug until 100 days after the last dose of study drug or the initiation of any subsequent cancer treatment, whichever occurs first (maximum exposure: 638 days)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological or cytological diagnosis of a relevant tumor type as per the study protocol and not candidates for curative surgery or radiation therapy\n* Available tumor tissue (archival or newly obtained core or excisional biopsy)\n* Adequate hematologic and end organ function as measured by laboratory screening panel in the 14 days prior to treatment\n* Life expectancy greater than 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Adequate contraception for women of childbearing potential\n* Pre-specified wash-out of prior anti-PD1/PDL-1 therapy\n\nExclusion Criteria:\n\n* Concurrent active malignancy\n* Major surgery within 4 weeks of treatment\n* Participants with active, known or suspected autoimmune diseases\n* Prior treatment with cluster of differentiation (CD) 137 agonists, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibodies\n* History of any Grade 3 or 4 immune-related adverse event (AE) toxicity from prior immunotherapy that resulted in treatment discontinuation\n* History of immune-related adverse events that lead to discontinuation of anti-PD-1 or PDL-1 therapy\n* Active infections of human immunodeficiency virus (HIV), hepatitis B, hepatitis C\n* Medical illness or abnormal laboratory finding that would, in the Study Investigator's judgement, increase the risk to the participant associated with participation in the study\n* Pregnancy in female participants",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Mereo Investigator Site",
          "city": "Phoenix",
          "state": "Arizona",
          "zip": "85054",
          "country": "United States",
          "geoPoint": {
            "lat": 33.44838,
            "lon": -112.07404
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Greenbrae",
          "state": "California",
          "zip": "94904",
          "country": "United States",
          "geoPoint": {
            "lat": 37.94854,
            "lon": -122.5247
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90025",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Jacksonville",
          "state": "Florida",
          "zip": "32224",
          "country": "United States",
          "geoPoint": {
            "lat": 30.33218,
            "lon": -81.65565
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02215",
          "country": "United States",
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Ann Arbor",
          "state": "Michigan",
          "zip": "48109",
          "country": "United States",
          "geoPoint": {
            "lat": 42.27756,
            "lon": -83.74088
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Rochester",
          "state": "Minnesota",
          "zip": "55905",
          "country": "United States",
          "geoPoint": {
            "lat": 44.02163,
            "lon": -92.4699
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "New York",
          "state": "New York",
          "zip": "10065",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Durham",
          "state": "North Carolina",
          "zip": "27710",
          "country": "United States",
          "geoPoint": {
            "lat": 35.99403,
            "lon": -78.89862
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Oklahoma City",
          "state": "Oklahoma",
          "zip": "73104",
          "country": "United States",
          "geoPoint": {
            "lat": 35.46756,
            "lon": -97.51643
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Nashville",
          "state": "Tennessee",
          "zip": "37203",
          "country": "United States",
          "geoPoint": {
            "lat": 36.16589,
            "lon": -86.78444
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "West Valley City",
          "state": "Utah",
          "zip": "84119",
          "country": "United States",
          "geoPoint": {
            "lat": 40.69161,
            "lon": -112.00105
          }
        },
        {
          "facility": "Mereo Investigator Site",
          "city": "Fairfax",
          "state": "Virginia",
          "zip": "22031",
          "country": "United States",
          "geoPoint": {
            "lat": 38.84622,
            "lon": -77.30637
          }
        },
        {
          "facility": "Royal Marsden",
          "city": "London",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        },
        {
          "facility": "Sarah Cannon UK",
          "city": "London",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "preAssignmentDetails": "Cohort D (Recurrent advanced and/or metastatic gastric or gastroesophageal junction adenocarcinoma) did not enroll any participants due to closure of the cohort by the Sponsor.",
      "groups": [
        {
          "id": "FG000",
          "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
          "description": "Participants with endometrial cancer checkpoint inhibitors (CPI) (programmed death-1 \\[PD-1\\]/ programmed death ligand-1 \\[PD-L1\\]) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "FG001",
          "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
          "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "FG002",
          "title": "Cohort C: Cervical Carcinoma",
          "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "FG003",
          "title": "Cohort E: TMB-H + MSS Solid Tumors",
          "description": "Participants with tumour mutational burden-high (TMB-H) and microsatellite stable (MSS) solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "FG004",
          "title": "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
          "description": "Participants with rare tumors (sarcoma, uveal melanoma, and germ cell) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "FG005",
          "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
          "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "FG006",
          "title": "Cohort H: Ovarian Cancer",
          "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "11"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "8"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "9"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "33"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "10"
                }
              ]
            },
            {
              "type": "Received at Least 1 Dose of Study Drug",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "11"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "8"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "9"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "33"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "10"
                }
              ]
            },
            {
              "type": "Response-Evaluable (RE) Analysis Set",
              "comment": "Participants with measurable disease at baseline who received study drug and had at least 1 post-baseline response assessment or discontinued treatment due to disease progression (including death due to disease progression) within 16 weeks (+ a 2-week window) of the first dose of study drug.",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "10"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "8"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "9"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "31"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "10"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "11"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "8"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "9"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "32"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "10"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Progressive Disease",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "2"
                }
              ]
            },
            {
              "type": "Protocol Violation",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Death",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "5"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "14"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "5"
                }
              ]
            },
            {
              "type": "Lost to Follow-up",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "1"
                }
              ]
            },
            {
              "type": "Study Terminated by Sponsor",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "5"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "10"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "2"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "populationDescription": "Safety Analysis Set included all participants who received any amount of study drug.",
      "groups": [
        {
          "id": "BG000",
          "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
          "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG001",
          "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
          "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG002",
          "title": "Cohort C: Cervical Carcinoma",
          "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG003",
          "title": "Cohort E: TMB-H + MSS Solid Tumors",
          "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG004",
          "title": "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
          "description": "Participants with rare tumors (sarcoma, uveal melanoma, and germ cell) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG005",
          "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
          "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG006",
          "title": "Cohort H: Ovarian Cancer",
          "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
        },
        {
          "id": "BG007",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "11"
            },
            {
              "groupId": "BG001",
              "value": "1"
            },
            {
              "groupId": "BG002",
              "value": "8"
            },
            {
              "groupId": "BG003",
              "value": "9"
            },
            {
              "groupId": "BG004",
              "value": "33"
            },
            {
              "groupId": "BG005",
              "value": "4"
            },
            {
              "groupId": "BG006",
              "value": "10"
            },
            {
              "groupId": "BG007",
              "value": "76"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "65.7",
                      "spread": "10.20"
                    },
                    {
                      "groupId": "BG001",
                      "value": "69.0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "49.1",
                      "spread": "13.53"
                    },
                    {
                      "groupId": "BG003",
                      "value": "62.0",
                      "spread": "10.14"
                    },
                    {
                      "groupId": "BG004",
                      "value": "55.8",
                      "spread": "13.90"
                    },
                    {
                      "groupId": "BG005",
                      "value": "65.3",
                      "spread": "11.79"
                    },
                    {
                      "groupId": "BG006",
                      "value": "68.1",
                      "spread": "11.43"
                    },
                    {
                      "groupId": "BG007",
                      "value": "59.5",
                      "spread": "13.51"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "11"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "8"
                    },
                    {
                      "groupId": "BG003",
                      "value": "4"
                    },
                    {
                      "groupId": "BG004",
                      "value": "10"
                    },
                    {
                      "groupId": "BG005",
                      "value": "4"
                    },
                    {
                      "groupId": "BG006",
                      "value": "10"
                    },
                    {
                      "groupId": "BG007",
                      "value": "47"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "5"
                    },
                    {
                      "groupId": "BG004",
                      "value": "23"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "29"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "1"
                    },
                    {
                      "groupId": "BG004",
                      "value": "3"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "8"
                    },
                    {
                      "groupId": "BG003",
                      "value": "8"
                    },
                    {
                      "groupId": "BG004",
                      "value": "30"
                    },
                    {
                      "groupId": "BG005",
                      "value": "4"
                    },
                    {
                      "groupId": "BG006",
                      "value": "10"
                    },
                    {
                      "groupId": "BG007",
                      "value": "71"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "2"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "2"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "8"
                    },
                    {
                      "groupId": "BG003",
                      "value": "9"
                    },
                    {
                      "groupId": "BG004",
                      "value": "31"
                    },
                    {
                      "groupId": "BG005",
                      "value": "2"
                    },
                    {
                      "groupId": "BG006",
                      "value": "8"
                    },
                    {
                      "groupId": "BG007",
                      "value": "69"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "2"
                    },
                    {
                      "groupId": "BG007",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Objective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)",
          "description": "The ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1. CR: Disappearance of all target or non-target lesions and normalization of tumor marker level. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \\<10 millimeters (mm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.",
          "populationDescription": "RE Analysis Set included all participants with measurable disease at baseline who received study drug and had at least 1 post-baseline response assessment or discontinued treatment due to disease progression (including death due to disease progression) within 16 weeks (+ a 2-week window) of the first dose of study drug. Per planned analysis, the efficacy data for Cohort F were collected and analyzed separately per tumor type.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "From first dose of study drug until the date of first objective response (CR or PR) (maximum exposure: 638 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
              "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG001",
              "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
              "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG002",
              "title": "Cohort C: Cervical Carcinoma",
              "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG003",
              "title": "Cohort E: TMB-H + MSS Solid Tumors",
              "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG004",
              "title": "Cohort F: Rare Tumors (Uveal)",
              "description": "Participants with rare tumors (uveal) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG005",
              "title": "Cohort F: Rare Tumors (De-diff LPS)",
              "description": "Participants with rare tumors (de-differentiated liposarcoma \\[de-diff LPS\\]) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG006",
              "title": "Cohort F: Rare Tumors (UPS)",
              "description": "Participants with rare tumors (undifferentiated pleomorphic sarcoma \\[UPS\\]) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG007",
              "title": "Cohort F: Rare Tumors (Other Sarcoma)",
              "description": "Participants with rare tumors (other sarcoma) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG008",
              "title": "Cohort F: Rare Tumors (GCT)",
              "description": "Participants with rare tumors (germ cell tumours \\[GCT\\]) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG009",
              "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
              "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG010",
              "title": "Cohort H: Ovarian Cancer",
              "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "1"
                },
                {
                  "groupId": "OG002",
                  "value": "8"
                },
                {
                  "groupId": "OG003",
                  "value": "9"
                },
                {
                  "groupId": "OG004",
                  "value": "8"
                },
                {
                  "groupId": "OG005",
                  "value": "10"
                },
                {
                  "groupId": "OG006",
                  "value": "6"
                },
                {
                  "groupId": "OG007",
                  "value": "3"
                },
                {
                  "groupId": "OG008",
                  "value": "4"
                },
                {
                  "groupId": "OG009",
                  "value": "3"
                },
                {
                  "groupId": "OG010",
                  "value": "10"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20.0",
                      "lowerLimit": "2.52",
                      "upperLimit": "55.61"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "97.50"
                    },
                    {
                      "groupId": "OG002",
                      "value": "37.5",
                      "lowerLimit": "8.52",
                      "upperLimit": "75.51"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "33.63"
                    },
                    {
                      "groupId": "OG004",
                      "value": "25.0",
                      "lowerLimit": "3.19",
                      "upperLimit": "65.09"
                    },
                    {
                      "groupId": "OG005",
                      "value": "10.0",
                      "lowerLimit": "0.25",
                      "upperLimit": "44.50"
                    },
                    {
                      "groupId": "OG006",
                      "value": "16.7",
                      "lowerLimit": "0.42",
                      "upperLimit": "64.12"
                    },
                    {
                      "groupId": "OG007",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "70.76"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "60.24"
                    },
                    {
                      "groupId": "OG009",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "70.76"
                    },
                    {
                      "groupId": "OG010",
                      "value": "10.0",
                      "lowerLimit": "0.25",
                      "upperLimit": "44.50"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants WithTreatment-emergent Adverse Events (TEAEs), Any Adverse Events of Special Interests (AESIs), AESI Immune Related AEs, and AESI Infusion Reactions",
          "description": "TEAEs were defined as adverse events (AEs) with an onset date on or after the date of first administration of study drug up to 100 days after the last dose of study drug and before starting any subsequent cancer treatment. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AESIs were defined as events (serious or non-serious) which were of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor might be appropriate. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.",
          "populationDescription": "Safety Analysis Set included all participants who received any amount of study drug.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "From first dose of study drug until 100 days after the last dose of study drug or the initiation of any subsequent cancer treatment, whichever occurs first (maximum exposure: 638 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
              "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG001",
              "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
              "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG002",
              "title": "Cohort C: Cervical Carcinoma",
              "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG003",
              "title": "Cohort E: TMB-H + MSS Solid Tumors",
              "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG004",
              "title": "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
              "description": "Participants with rare tumors (sarcoma, uveal melanoma, and germ cell) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG005",
              "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
              "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG006",
              "title": "Cohort H: Ovarian Cancer",
              "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "11"
                },
                {
                  "groupId": "OG001",
                  "value": "1"
                },
                {
                  "groupId": "OG002",
                  "value": "8"
                },
                {
                  "groupId": "OG003",
                  "value": "9"
                },
                {
                  "groupId": "OG004",
                  "value": "33"
                },
                {
                  "groupId": "OG005",
                  "value": "4"
                },
                {
                  "groupId": "OG006",
                  "value": "10"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Any TEAEs",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "11"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    },
                    {
                      "groupId": "OG002",
                      "value": "8"
                    },
                    {
                      "groupId": "OG003",
                      "value": "8"
                    },
                    {
                      "groupId": "OG004",
                      "value": "33"
                    },
                    {
                      "groupId": "OG005",
                      "value": "4"
                    },
                    {
                      "groupId": "OG006",
                      "value": "9"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Any AESIs",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "3"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "5"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "AESI Immune Related AEs",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "2"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "3"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "AESI Infusion Reactions",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "1"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "2"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Disease Control Rate (DCR) as Assessed Based on RECIST v1.1",
          "description": "The DCR was defined as the percentage of participants who achieved CR, PR, and stable disease (SD). CR: Disappearance of all target or non-target lesions and normalization of tumor marker level. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits; and no new lesions.",
          "populationDescription": "RE Analysis Set included all participants with measurable disease at baseline who received study drug and had at least 1 post-baseline response assessment or discontinued treatment due to disease progression (including death due to disease progression) within 16 weeks (+ a 2-week window) of the first dose of study drug. Per planned analysis, the efficacy data for Cohort F were collected and analyzed separately per tumor type.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "From first dose of study drug until the date of first BOR (CR, PR, or SD) (maximum exposure: 638 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
              "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG001",
              "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
              "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG002",
              "title": "Cohort C: Cervical Carcinoma",
              "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG003",
              "title": "Cohort E: TMB-H + MSS Solid Tumors",
              "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG004",
              "title": "Cohort F: Rare Tumors (Uveal)",
              "description": "Participants with rare tumors (uveal) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG005",
              "title": "Cohort F: Rare Tumors (De-diff LPS)",
              "description": "Participants with rare tumors (de-diff LPS) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG006",
              "title": "Cohort F: Rare Tumors (UPS)",
              "description": "Participants with rare tumors (UPS) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG007",
              "title": "Cohort F: Rare Tumors (Other Sarcoma)",
              "description": "Participants with rare tumors (other sarcoma) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG008",
              "title": "Cohort F: Rare Tumors (GCT)",
              "description": "Participants with rare tumors (GCT) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG009",
              "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
              "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG010",
              "title": "Cohort H: Ovarian Cancer",
              "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "1"
                },
                {
                  "groupId": "OG002",
                  "value": "8"
                },
                {
                  "groupId": "OG003",
                  "value": "9"
                },
                {
                  "groupId": "OG004",
                  "value": "8"
                },
                {
                  "groupId": "OG005",
                  "value": "10"
                },
                {
                  "groupId": "OG006",
                  "value": "6"
                },
                {
                  "groupId": "OG007",
                  "value": "3"
                },
                {
                  "groupId": "OG008",
                  "value": "4"
                },
                {
                  "groupId": "OG009",
                  "value": "3"
                },
                {
                  "groupId": "OG010",
                  "value": "10"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "50.0",
                      "lowerLimit": "18.71",
                      "upperLimit": "81.29"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "97.50"
                    },
                    {
                      "groupId": "OG002",
                      "value": "62.5",
                      "lowerLimit": "24.49",
                      "upperLimit": "91.48"
                    },
                    {
                      "groupId": "OG003",
                      "value": "33.3",
                      "lowerLimit": "7.49",
                      "upperLimit": "70.07"
                    },
                    {
                      "groupId": "OG004",
                      "value": "50.0",
                      "lowerLimit": "15.70",
                      "upperLimit": "84.3"
                    },
                    {
                      "groupId": "OG005",
                      "value": "50.0",
                      "lowerLimit": "18.71",
                      "upperLimit": "81.29"
                    },
                    {
                      "groupId": "OG006",
                      "value": "33.3",
                      "lowerLimit": "4.33",
                      "upperLimit": "77.72"
                    },
                    {
                      "groupId": "OG007",
                      "value": "33.3",
                      "lowerLimit": "0.84",
                      "upperLimit": "90.57"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "60.24"
                    },
                    {
                      "groupId": "OG009",
                      "value": "0",
                      "lowerLimit": "0.00",
                      "upperLimit": "70.76"
                    },
                    {
                      "groupId": "OG010",
                      "value": "60.0",
                      "lowerLimit": "26.24",
                      "upperLimit": "87.84"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Duration of Response (DoR) as Assessed Based on RECIST v1.1",
          "description": "The DoR was defined as the time, in days, from the first of the 2 assessments required for confirmed PR or CR to the time of the progressive disease (PD) or death due to underlying cancer. CR: Disappearance of all target or non-target lesions and normalization of tumor marker level. Any pathological lymph node (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of the existing non-target lesions. The appearance of one or more new lesions was also considered progression.",
          "populationDescription": "RE Analysis Set: all participants with measurable disease at baseline who received study drug and had at least 1 post-baseline response assessment or discontinued treatment due to disease progression (including death due to disease progression) within 16 weeks of first dose of study drug. Per planned analysis, the efficacy data for Cohort F were collected and analyzed separately per tumor type. 'Overall number of participants analyzed' = participants evaluable for this outcome measure.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "days",
          "timeFrame": "From first dose of study drug until the date of first overall response of PD or date of death due to underlying cancer (maximum exposure: 638 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
              "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG001",
              "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
              "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG002",
              "title": "Cohort C: Cervical Carcinoma",
              "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG003",
              "title": "Cohort E: TMB-H + MSS Solid Tumors",
              "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG004",
              "title": "Cohort F: Rare Tumors (Uveal)",
              "description": "Participants with rare tumors (uveal) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG005",
              "title": "Cohort F: Rare Tumors (De-diff LPS)",
              "description": "Participants with rare tumors (de-diff LPS) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG006",
              "title": "Cohort F: Rare Tumors (UPS)",
              "description": "Participants with rare tumors (UPS) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG007",
              "title": "Cohort F: Rare Tumors (Other Sarcoma)",
              "description": "Participants with rare tumors (other sarcoma) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG008",
              "title": "Cohort F: Rare Tumors (GCT)",
              "description": "Participants with rare tumors (GCT) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG009",
              "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
              "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG010",
              "title": "Cohort H: Ovarian Cancer",
              "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "2"
                },
                {
                  "groupId": "OG001",
                  "value": "0"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "0"
                },
                {
                  "groupId": "OG004",
                  "value": "2"
                },
                {
                  "groupId": "OG005",
                  "value": "1"
                },
                {
                  "groupId": "OG006",
                  "value": "1"
                },
                {
                  "groupId": "OG007",
                  "value": "0"
                },
                {
                  "groupId": "OG008",
                  "value": "0"
                },
                {
                  "groupId": "OG009",
                  "value": "0"
                },
                {
                  "groupId": "OG010",
                  "value": "1"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "197.0",
                      "lowerLimit": "57",
                      "upperLimit": "337"
                    },
                    {
                      "groupId": "OG002",
                      "value": "183.0",
                      "lowerLimit": "64",
                      "upperLimit": "360"
                    },
                    {
                      "groupId": "OG004",
                      "value": "307.0",
                      "lowerLimit": "92",
                      "upperLimit": "522"
                    },
                    {
                      "groupId": "OG005",
                      "value": "464.0",
                      "lowerLimit": "464",
                      "upperLimit": "464"
                    },
                    {
                      "groupId": "OG006",
                      "value": "145.0",
                      "lowerLimit": "145",
                      "upperLimit": "145"
                    },
                    {
                      "groupId": "OG010",
                      "value": "442.0",
                      "lowerLimit": "442",
                      "upperLimit": "442"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Duration of Stable Disease (DoSD) as Assessed Based on RECIST v1.1",
          "description": "The DoSD was defined as the time, in days, from the first date of treatment until the first date at which PD was experienced or the participant died due to underlying cancer. PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of the existing non-target lesions. The appearance of one or more new lesions was also considered progression.",
          "populationDescription": "RE Analysis Set included all participants with measurable disease at baseline who received study drug and had at least 1 post-baseline response assessment or discontinued treatment due to disease progression (including death due to disease progression) within 16 weeks (+ a 2-week window) of the first dose of study drug. Per planned analysis, the efficacy data for Cohort F were collected and analyzed separately per tumor type.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "days",
          "timeFrame": "From first dose of study drug until the date of first overall response of PD or date of death due to underlying cancer (up to a maximum of 680 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
              "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG001",
              "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
              "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG002",
              "title": "Cohort C: Cervical Carcinoma",
              "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG003",
              "title": "Cohort E: TMB-H + MSS Solid Tumors",
              "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG004",
              "title": "Cohort F: Rare Tumors (Uveal)",
              "description": "Participants with rare tumors (uveal) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG005",
              "title": "Cohort F: Rare Tumors (De-diff LPS)",
              "description": "Participants with rare tumors (de-diff LPS) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG006",
              "title": "Cohort F: Rare Tumors (UPS)",
              "description": "Participants with rare tumors (UPS) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG007",
              "title": "Cohort F: Rare Tumors (Other Sarcoma)",
              "description": "Participants with rare tumors (other sarcoma) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG008",
              "title": "Cohort F: Rare Tumors (GCT)",
              "description": "Participants with rare tumors (GCT) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG009",
              "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
              "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG010",
              "title": "Cohort H: Ovarian Cancer",
              "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "10"
                },
                {
                  "groupId": "OG001",
                  "value": "1"
                },
                {
                  "groupId": "OG002",
                  "value": "8"
                },
                {
                  "groupId": "OG003",
                  "value": "9"
                },
                {
                  "groupId": "OG004",
                  "value": "8"
                },
                {
                  "groupId": "OG005",
                  "value": "10"
                },
                {
                  "groupId": "OG006",
                  "value": "6"
                },
                {
                  "groupId": "OG007",
                  "value": "3"
                },
                {
                  "groupId": "OG008",
                  "value": "4"
                },
                {
                  "groupId": "OG009",
                  "value": "3"
                },
                {
                  "groupId": "OG010",
                  "value": "10"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "81.5",
                      "lowerLimit": "50",
                      "upperLimit": "423"
                    },
                    {
                      "groupId": "OG001",
                      "value": "45.0",
                      "lowerLimit": "45",
                      "upperLimit": "45"
                    },
                    {
                      "groupId": "OG002",
                      "value": "120.0",
                      "lowerLimit": "50",
                      "upperLimit": "414"
                    },
                    {
                      "groupId": "OG003",
                      "value": "57.0",
                      "lowerLimit": "45",
                      "upperLimit": "140"
                    },
                    {
                      "groupId": "OG004",
                      "value": "109.5",
                      "lowerLimit": "52",
                      "upperLimit": "680"
                    },
                    {
                      "groupId": "OG005",
                      "value": "108.0",
                      "lowerLimit": "36",
                      "upperLimit": "568"
                    },
                    {
                      "groupId": "OG006",
                      "value": "55.5",
                      "lowerLimit": "16",
                      "upperLimit": "337"
                    },
                    {
                      "groupId": "OG007",
                      "value": "53.0",
                      "lowerLimit": "52",
                      "upperLimit": "60"
                    },
                    {
                      "groupId": "OG008",
                      "value": "57.5",
                      "lowerLimit": "56",
                      "upperLimit": "58"
                    },
                    {
                      "groupId": "OG009",
                      "value": "50.0",
                      "lowerLimit": "50",
                      "upperLimit": "58"
                    },
                    {
                      "groupId": "OG010",
                      "value": "70.0",
                      "lowerLimit": "37",
                      "upperLimit": "547"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Serum Concentrations of Etigilimab",
          "populationDescription": "The pharmacokinetic (PK) analysis set included all participants with sufficient plasma concentration data to allow the characterization of the PK parameters. Per planned analysis, PK data were collected and analyzed combined for all arm groups. 'Number analyzed' = participants evaluable at specified timepoint.",
          "reportingStatus": "POSTED",
          "paramType": "GEOMETRIC_MEAN",
          "dispersionType": "Geometric Coefficient of Variation",
          "unitOfMeasure": "micrograms (g)/milliliter (mL)",
          "timeFrame": "Pre-infusion and 15 minutes post-infusion on Cycle 1 Day 1 and Cycle 4 Day 43",
          "groups": [
            {
              "id": "OG000",
              "title": "Etigilimab",
              "description": "Participants received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "30"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Cycle 1 Day 1 (Pre-infusion)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "30"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "spread": "NA",
                      "comment": "Sample below the limit of quantification (0.200 g/mL)."
                    }
                  ]
                }
              ]
            },
            {
              "title": "Cycle 1 Day 1 (15 minutes post-infusion)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "29"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "262",
                      "spread": "22"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Cycle 4 Day 43 (Pre-infusion)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "25"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20.1",
                      "spread": "82"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Cycle 4 Day 43 (15 minutes post-infusion)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "25"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "273",
                      "spread": "27"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants With Anti-drug Antibodies (ADA) to Etigilimab",
          "populationDescription": "The immunogenicity analysis set included all participants with at least 1 evaluable post-treatment immunogenicity sample.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "From first dose of study drug until 100 days after the last dose of study drug or the initiation of any subsequent cancer treatment, whichever occurs first (maximum exposure: 638 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
              "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG001",
              "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
              "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG002",
              "title": "Cohort C: Cervical Carcinoma",
              "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG003",
              "title": "Cohort E: TMB-H + MSS Solid Tumors",
              "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG004",
              "title": "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
              "description": "Participants with rare tumors (sarcoma, uveal melanoma, and germ cell) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG005",
              "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
              "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            },
            {
              "id": "OG006",
              "title": "Cohort H: Ovarian Cancer",
              "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "1"
                },
                {
                  "groupId": "OG002",
                  "value": "1"
                },
                {
                  "groupId": "OG003",
                  "value": "0"
                },
                {
                  "groupId": "OG004",
                  "value": "6"
                },
                {
                  "groupId": "OG005",
                  "value": "0"
                },
                {
                  "groupId": "OG006",
                  "value": "1"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "timeFrame": "From first dose of study drug until 100 days after the last dose of study drug or the initiation of any subsequent cancer treatment, whichever occurs first (maximum exposure: 638 days)",
      "description": "Safety Analysis Set included all participants who received any amount of study drug.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive",
          "description": "Participants with endometrial cancer CPI (PD-1/PD-L1) naive received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 2,
          "deathsNumAtRisk": 11,
          "seriousNumAffected": 2,
          "seriousNumAtRisk": 11,
          "otherNumAffected": 11,
          "otherNumAtRisk": 11
        },
        {
          "id": "EG001",
          "title": "Cohort B: Head and Neck Squamous Cell Carcinoma",
          "description": "Participants with head and neck cell carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 1,
          "deathsNumAtRisk": 1,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 1,
          "otherNumAffected": 1,
          "otherNumAtRisk": 1
        },
        {
          "id": "EG002",
          "title": "Cohort C: Cervical Carcinoma",
          "description": "Participants with cervical carcinoma received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 2,
          "deathsNumAtRisk": 8,
          "seriousNumAffected": 2,
          "seriousNumAtRisk": 8,
          "otherNumAffected": 8,
          "otherNumAtRisk": 8
        },
        {
          "id": "EG003",
          "title": "Cohort E: TMB-H + MSS Solid Tumors",
          "description": "Participants with TMB-H and MSS solid tumors received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 5,
          "deathsNumAtRisk": 9,
          "seriousNumAffected": 5,
          "seriousNumAtRisk": 9,
          "otherNumAffected": 8,
          "otherNumAtRisk": 9
        },
        {
          "id": "EG004",
          "title": "Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell)",
          "description": "Participants with rare tumors (sarcoma, uveal melanoma, and germ cell) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 14,
          "deathsNumAtRisk": 33,
          "seriousNumAffected": 8,
          "seriousNumAtRisk": 33,
          "otherNumAffected": 33,
          "otherNumAtRisk": 33
        },
        {
          "id": "EG005",
          "title": "Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated)",
          "description": "Participants with endometrial cancer (PD-1/PD-L1 treated) received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 2,
          "deathsNumAtRisk": 4,
          "seriousNumAffected": 2,
          "seriousNumAtRisk": 4,
          "otherNumAffected": 4,
          "otherNumAtRisk": 4
        },
        {
          "id": "EG006",
          "title": "Cohort H: Ovarian Cancer",
          "description": "Participants with ovarian cancer received etigilimab in combination with nivolumab every 2 weeks and continued treatment until protocol-defined discontinuation criteria were met.",
          "deathsNumAffected": 5,
          "deathsNumAtRisk": 10,
          "seriousNumAffected": 3,
          "seriousNumAtRisk": 10,
          "otherNumAffected": 9,
          "otherNumAtRisk": 10
        }
      ],
      "seriousEvents": [
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Sepsis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Abdominal sepsis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Peritonitis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Septic shock",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Abdominal pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Ascites",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Immune-mediated gastritis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Intestinal obstruction",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Malignant ascites",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Small intestinal obstruction",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Pleural effusion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Chylothorax",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Disease progression",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Urinary tract obstruction",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Acute kidney injury",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Atrial fibrillation",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Myocardial infarction",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Arthralgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Muscular weakness",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Musculoskeletal chest pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Adrenal insufficiency",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Decreased appetite",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Hypoaesthesia",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Pelvic pain",
          "organSystem": "Reproductive system and breast disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 6,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 4,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Constipation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 5,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 6,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Abdominal pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Rash",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 11,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Pruritus",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Rash maculo-papular",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Dry skin",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Dermatitis",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 14,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Oedema peripheral",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Chills",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Influenza like illness",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Decreased appetite",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 4,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Hyponatraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Dehydration",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Hypoalbuminaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 7,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Arthralgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 7,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Pain in extremity",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Muscular weakness",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "COVID-19",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Upper respiratory tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Urinary tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Aspartate aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Weight decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Alanine aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Blood creatinine increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 10,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Paraesthesia",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Hypertension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Infusion related reaction",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Fall",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Anxiety",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Insomnia",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        },
        {
          "term": "Hypothyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 11
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 8
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 9
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 33
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 10
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "OTHER",
        "restrictiveAgreement": true,
        "otherDetails": "All PIs must seek written permission from the sponsor before publication of any trial results."
      },
      "pointOfContact": {
        "title": "Mereo BioPharma",
        "organization": "Mereo BioPharma",
        "email": "enquiries@mereobiopharma.com",
        "phone": "Please Email"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2022-06-29",
          "uploadDate": "2025-01-28T14:34",
          "filename": "Prot_000.pdf",
          "size": 7556141
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2023-11-08",
          "uploadDate": "2025-01-28T14:35",
          "filename": "SAP_001.pdf",
          "size": 2102469
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-02",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2025-02-24",
            "type": "ACTUAL"
          }
        }
      }
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D009362",
          "term": "Neoplasm Metastasis"
        }
      ],
      "ancestors": [
        {
          "id": "D009385",
          "term": "Neoplastic Processes"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000077594",
          "term": "Nivolumab"
        }
      ],
      "ancestors": [
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": true
}